ROCKVILLE, Md., April 28, 2020 /PRNewswire/ -- REGENXBIO
Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology
company seeking to improve lives through the curative potential of
gene therapy based on its proprietary
NAV® Technology Platform, today announced that
three oral presentations, and several poster presentations, will be
presented at the American Society of Gene and Cell Therapy's
23rd Annual Meeting taking place May 12-15, 2020 in virtual format. Presentations
and posters will be available at www.asgct.org.
The oral presentations include:
Abstract Title: Quantitative PET/CT based
pharmacokinetic study of AAV9 administered to the cerebrospinal
fluid of non-human primates (abstract #135)
Session Title: AAV Vectors Preclinical and
Proof-of-Concept Studies in Optimizing the Toolbox
Presenter: Mikhail Papisov, Ph.D., Massachusetts General
Hospital, Shriners Hospitals for Children, Harvard Medical School
Date/Time: Tuesday, May 12, 2020 from 4:00 - 4:15 p.m. ET
Abstract Title: RGX-314 Ocular Gene Therapy:
Overview of Phase I/IIa Ongoing Trial for Neovascular Age-related
Macular Degeneration (nAMD) and Future Directions (abstract
#1305)
Session Title: AAV Vectors - Clinical Studies
Presenter: Olivier Danos,
Ph.D., Senior Vice President and Chief Scientific Officer,
REGENXBIO
Date/Time: Friday, May 15,
2020 from 10:15-10:30 a.m.
ET
Abstract Title: AAV gene therapy in
mucopolysaccharidosis IVA murine models (abstract #1351)
Session Title: Gene Therapy for Inborn Errors of
Metabolism: New Approaches
Presenter: Shunji Tomatsu,
M.D., Ph.D., Nemours/Alfred I. duPont Hospital for Children
Date/Time: Friday, May 15, 2020 from 11:15-11:30 a.m. ET
The posters include:
Abstract Title: AAV-mediated antibody delivery for
hereditary angioedema (abstract #190)
Presenter: Joseph T. Bruder,
Ph.D., Senior Director, Target Discovery, REGENXBIO
Session Title: AAV Vectors - Preclinical and
Proof-of-Concept Studies
Date/Time: Tuesday, May 12, 2020 from 5:30-6:30 p.m. ET
Abstract Title: Interim data from the first in human
RGX-121 gene therapy trial for the treatment of severe MPS II
(Hunter syndrome) (abstract #614)
Presenter: Marie-Laure
Nevoret, M.D., Senior Clinical Development Lead,
REGENXBIO
Session Title: AAV Vectors - Clinical Studies
Date/Time: Wednesday, May 13, 2020 from 5:30-6:30 p.m. ET
Abstract Title: Development of a vectorized antibody
platform for liver and skeletal muscle gene transfer (abstract
#556)
Presenter: Devin S.
McDougald, Ph.D., Scientist II, Gene Transfer Technologies,
REGENXBIO
Session Title: AAV Vectors – Virology &
Vectorology
Date/Time: Wednesday, May 13, 2020 from 5:30-6:30 p.m. ET
Abstract Title: Use of Prophylactic Steroids to
Mitigate Potential T-Cell Response in AAV8-Mediated
hLDLR Gene Transfer in Subjects with Homozygous
Familial Hypercholesterolemia (abstract #612)
Presenter: Marina Cuchel,
M.D., Ph.D., University of
Pennsylvania
Session Title: AAV Vectors - Clinical Studies
Date/Time: Wednesday, May 13, 2020 from 5:30-6:30 p.m. ET
Abstract Title: Process development and scaleup
comparisons for transient Production of AAV (abstract #1266)
Presenter: Robert Stadelman,
Senior Scientist, REGENXBIO
Session Title: Vector and Cell Engineering, Production or
Manufacturing
Date/Time: Thursday, May 14, 2020 from 5:30-6:30 p.m. ET
Abstract Title: Structural and biochemical
characterization of potentially under-utilized gene therapy vector
AAV7 (abstract #1007)
Presenter: Samantha A. Yost,
Ph.D., Scientist II, Gene Transfer Technologies, REGENXBIO
Session Title: AAV Vectors - Virology and
Vectorology
Date/Time: Thursday, May 14, 2020 from 5:30-6:30 p.m. ET
Abstract Title: Development of a Sensitive and
Robust Cell-Based Assay for Measuring Potency of the NAV AAV8
Vector-Derived RGX-314 Gene Therapy Product for the Treatment of
Wet Age-Related Macular Degeneration (abstract #1005)
Presenter: Raza Zaidi, Senior
Associate Scientist, REGENXBIO
Session Title: AAV Vectors - Virology and
Vectorology
Date/Time: Thursday, May 14, 2020 from 5:30-6:30 p.m. ET
About REGENXBIO Inc.
REGENXBIO is a leading
clinical-stage biotechnology company seeking to improve lives
through the curative potential of gene
therapy. REGENXBIO's NAV Technology Platform, a
proprietary adeno-associated virus (AAV) gene delivery platform,
consists of exclusive rights to more than 100 novel AAV vectors,
including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its
third-party NAV Technology Platform Licensees are applying the NAV
Technology Platform in the development of a broad pipeline of
candidates in multiple therapeutic areas.
Contacts:
Tricia
Truehart
Investor Relations and Corporate Communications
347-926-7709
ttruehart@regenxbio.com
Investors:
Heather Savelle, 212-600-1902
heather@argotpartners.com
Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/regenxbio-announces-presentations-at-the-american-society-of-gene-and-cell-therapys-23rd-annual-meeting-301048853.html
SOURCE REGENXBIO Inc.